Spyre Therapeutics reports SKYWAY RA sub-study topline results for SPY072
Spyre Therapeutics announces topline results from the rheumatoid arthritis sub-study of the SKYWAY Phase 2 trial of SPY072.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.